2023 Satellite - Improving Outcomes with SGLT2 Inhibitors in Patients with Heart Failure: From Evidence to Clinical Practice-Improving Outcomes with SGLT2 Inhibitors in Patients with Heart Failure: From Evidence to Clinical Practice

Improving Outcomes with SGLT2 Inhibitors in Patients with Heart Failure: From Evidence to Clinical Practice

Video Transcription

Video Summary

The video discusses the effectiveness and safety of SGLT2 inhibitors in heart failure patients, regardless of their ejection fraction (EF). It highlights that these inhibitors have been proven effective in patients with heart failure with mid-range EF (HFmrEF), heart failure with preserved EF (HFpEF), and heart failure with reduced EF (HFrEF). Subgroup analyses have shown that the efficacy of SGLT2 inhibitors is consistent across all ejection fractions, debunking the belief that they are more beneficial in patients with higher EF.<br /><br />The video also addresses the safety profile of SGLT2 inhibitors, noting that they have shown fewer serious adverse events compared to placebo and no significant safety concerns. They have been found to be equally safe in patients with mild or moderate renal impairment.<br /><br />Furthermore, the video mentions that SGLT2 inhibitors have potential survival benefits in patients with heart failure with improved EF. It discusses the positive impact of these inhibitors on symptom function, quality of life, and blood pressure control.<br /><br />In conclusion, the video recommends the use of SGLT2 inhibitors in heart failure patients, regardless of their ejection fraction. It suggests that these inhibitors be considered alongside other heart failure therapies for optimal management.

Keywords

SGLT2 inhibitors

heart failure

ejection fraction

HFmrEF

HFpEF

HFrEF

efficacy

safety

adverse events

renal impairment

survival benefits